CGRP Education & Research Forum
Already a member? Login Become a member Register
  • Home
  • About Us
    • About CGRP Forum
    • Editorial Board
  • About CGRP
    • About CGRP
    • CGRP and migraine
    • Unmet needs in migraine prevention
    • What is the role of CGRP in migraine?
    • Why is CGRP an important therapeutic target?
    • Migraine is a complex neurovascular condition
  • News
    • News
    • Meeting Reports
    • Real World Experience
  • Newsletter
  • Hot Topics
  • Videos
    • Meet the Expert: Issues and Answers
  • Trials
    • Atogepant (AGN-241689)
    • Erenumab (AMG 334)
    • Eptinezumab (ALD403)
    • Galcanezumab (LY2951742)
    • Fremanezumab (TEV-48125)
    • Rimegepant (BHV-3000)
    • Ubrogepant (MK-1602)
  • Resources
    • CGRP in the Journals
    • Meetings
    • Backgrounders
    • Slides
    • Links
    • Videos
  • Contact US
Hot off the press: New Forum launches
twitterfacebookyoutubeLinkedIn
Latest:
Should CGRP mAbs be first-line preventive treatment for migraine?DELIVER results confirm eptinezumab efficacy across sub-groupsSustained benefits of erenumab vs oral preventivesDaily headache does not impede response to galcanezumabInterim PEARL analysis supports real world efficacy of fremanezumabFurther evidence of CGRP rise after mAb treatmentTrigeminal symptoms may predict anti-CGRP mAb responseEligible patients with migraine still miss out on preventive therapies
Next image

messoud

31 May 2019 Full size 200 × 200

Post navigation

Published inFOCUS data show beneficial effects on migraine days and responder rates with fremanezumab in episodic and chronic migraine

Trials

  • Atogepant (AGN-241689)
  • Erenumab (AMG 334)
  • Galcanezumab (LY2951742)
  • Fremanezumab (TEV-48125)
  • Eptinezumab (ALD403)
  • Rimegepant (BHV-3000)
  • Ubrogepant (MK-1602)

Meeting Reports

  • 8th Congress of the European Academy of Neurology
  • 64th Annual Meeting of the American Headache Society
  • American Academy of Neurology 2022
  • XXV World Congress of Neurology 2021
  • International Headache Congress 2021
  • 7th Congress of the European Academy of Neurology
  • 63rd Annual Meeting of the American Headache Society
  • American Academy of Neurology 2021 Virtual Annual Meeting
  • Migraine Trust International Symposium 2020
  • 14th European Headache Federation Congress
  • 62nd Annual Meeting of the American Headache Society
  • 6th Congress of the European Academy of Neurology
  • American Academy of Neurology 2020
  • World Congress of Neurology 2019
  • IHC 2019
  • American Headache Society (AHS) 61st Annual Scientific Meeting
  • 5th Congress of the European Academy of Neurology
  • 13th European Headache Federation Congress
  • American Academy of Neurology Annual Meeting 2019
  • 12th European Headache Federation Congress
  • 17th Biennial Migraine Trust International Symposium
  • American Headache Society (AHS) 60th Annual Scientific Meeting
  • 4th Congress of the European Academy of Neurology
  • American Academy of Neurology (AAN) Congress
  • 11th European Headache Federation Congress
  • 18th Congress of the International Headache Society
  • American Headache Society Annual Scientific Meeting
  • 3rd Congress of the European Academy of Neurology
  • American Academy of Neurology Annual Meeting
  • Scottsdale Headache Symposium
  • ​​The European Headache and Migraine Trust International Congress (EHMTIC)

Resources

  • Slides
    • Migraine care in Brazil: the role of anti-CGRP therapies
    • Atogepant
    • Erenumab
    • Eptinezumab
  • Meetings
  • Links
Invite a colleague »

Educational Partners and Supporters (others pending) Amgen
Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Partnership & OutreachThrough its unique global network of researchers and clinicians, the CGRP Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of the burden, disability and cost associated with migraine.




© 2022 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |
MENU
  • Home
  • About Us
    • About CGRP Forum
    • Editorial Board
  • About CGRP
    • About CGRP
    • CGRP and migraine
    • Unmet needs in migraine prevention
    • What is the role of CGRP in migraine?
    • Why is CGRP an important therapeutic target?
    • Migraine is a complex neurovascular condition
  • News
    • News
    • Meeting Reports
    • Real World Experience
  • Newsletter
  • Hot Topics
  • Videos
    • Meet the Expert: Issues and Answers
  • Trials
    • Atogepant (AGN-241689)
    • Erenumab (AMG 334)
    • Eptinezumab (ALD403)
    • Galcanezumab (LY2951742)
    • Fremanezumab (TEV-48125)
    • Rimegepant (BHV-3000)
    • Ubrogepant (MK-1602)
  • Resources
    • CGRP in the Journals
    • Meetings
    • Backgrounders
    • Slides
    • Links
    • Videos
  • Contact US